Special Issue "Antibody-Drug Conjugate"

A special issue of Antibodies (ISSN 2073-4468).

Deadline for manuscript submissions: 1 October 2018

Special Issue Editors

Guest Editor
Dr. Penelope M. Drake

Catalent Biologics (formerly Redwood Bioscience), 5703 Hollis Street, Emeryville, CA 94608, USA
Website | E-Mail
Interests: Antibody-Drug Conjugate
Guest Editor
Dr. Mary Jane Masson Hinrichs

Biologics Safety Assessment, MedImmune LLC, 1 MedImmune Way, Gaithersburg, MD 20892, USA
E-Mail

Special Issue Information

Dear Colleagues,

Antibody-drug conjugates (ADCs) represent a rapidly evolving area of drug development and research. Four ADCs are now approved for the treatment of various oncology indications, with additional promising molecules in late stage trials. At the same time, lessons from clinical failures fuel preclinical research that is often quickly translated back into the clinic. Research areas of study include identifying novel target antigens, developing new linker/payload combinations, and widening the therapeutic index. Approaches to the latter include limiting off-target toxicity through more selective tumor targeting, reducing ADC hydrophobicity through linker or conjugation site variation, modifying dosing regimens for greater tolerability, and exploring payloads across a range of potencies.

This Special Issue of Antibodies will present recent work selected from across the ADC field, showcasing the range of current thinking among investigators and drug developers. Topics will include novel target antigens, bispecific/biparatopic and alternate protein formats, pharmacokinetic/pharmacodynamic studies, combination therapies and checkpoint inhibitor synergies, new conjugation or linker technologies, new payloads, theoretical modeling, and ADCs for non-oncology indications. We welcome manuscripts describing your latest innovations and look forward to a thought-provoking issue.

Dr. Penelope M. Drake
Dr. Mary Jane Masson Hinrichs
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 350 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Antibody-drug conjugate
  • Cytotoxic payload
  • Therapeutic index

Published Papers

This special issue is now open for submission, see below for planned papers.

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: Preclinical Considerations and Factors Affecting the Pharmacology of Antibody-Drug Conjugates

Authors: Andrew T Lucas, Lauren SL Price, Allison N Schorzman, Joseph A Piscitelli, Juan Razo, and William C Zamboni

Affiliations:

1) Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA (A.T.L., L.S.L.P., A.N.S, W.C.Z)

2) UNC Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA (J.A.P., J.R.)

3) Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA (A.T.L., W.C.Z)

Back to Top